Thurgood Lauren A, Chataway Tim K, Lower Karen M, Kuss Bryone J
Department of Haematology and Genetic Pathology, Flinders University, Adelaide, South Australia, Australia.
Department of Physiology, Flinders University, Adelaide, South Australia, Australia.
J Proteomics. 2017 Feb 23;155:73-84. doi: 10.1016/j.jprot.2017.01.001. Epub 2017 Jan 6.
Chronic lymphocytic leukemia (CLL) remains the most common leukemia in the Western world. Whilst its disease course is extremely heterogeneous (ranging from indolent to aggressive), current methods are unable to accurately predict the clinical journey of each patient. There is clearly a pressing need for both improved prognostication and treatment options for patients with this disease. Whilst molecular studies have analyzed both genetic mutations and gene expression profiles of these malignant B-cells, and as a result have shed light on the pathogenesis of CLL, proteomic studies have been largely overlooked to date. This review summarizes our current knowledge of the proteomics of CLL, and discusses some of the issues in CLL proteomic research, such as reproducibility and data interpretation. In addition, we look ahead to how proteomics may significantly help in the development of a successful treatment for this currently incurable disease.
慢性淋巴细胞白血病（CLL）仍是西方世界最常见的白血病。尽管其病程极具异质性（从惰性到侵袭性不等），但目前的方法无法准确预测每位患者的临床进程。显然，迫切需要改善这种疾病患者的预后评估和治疗选择。虽然分子研究已经分析了这些恶性B细胞的基因突变和基因表达谱，从而揭示了CLL的发病机制，但蛋白质组学研究迄今为止在很大程度上被忽视了。本综述总结了我们目前对CLL蛋白质组学的认识，并讨论了CLL蛋白质组学研究中的一些问题，如可重复性和数据解读。此外，我们展望蛋白质组学如何能够显著助力针对这种目前无法治愈的疾病开发出成功的治疗方法。
